Exploring Novel Adverse Events of Nefecon

Area of Science:

• Pharmacovigilance
• Nephrology
• Drug Safety

Background:

• Nefecon is the first FDA and EMA approved drug for IgA nephropathy (IgAN).
• Comprehensive real-world adverse event (AE) data for Nefecon was previously lacking.
• Postmarketing surveillance is crucial for understanding drug safety profiles.

Purpose of the Study:

• To conduct a real-world assessment of Nefecon's adverse events using US FDA FAERS data.
• To identify potential safety signals and characterize the AE profile of Nefecon in IgAN patients.
• To evaluate novel adverse events and assess clinical priority.

Main Methods:

• Utilized US FDA Adverse Event Reporting System (FAERS) postmarketing data.
• Employed disproportionate analysis (DPA) to detect safety signals at SOC and PT levels.
• Excluded duplicate and previously reported AEs using MedDRA; analyzed time-to-onset, cumulative incidence, and subgroup data.

Main Results:

• Identified 5 positive SOC signals and 23 positive PT signals.
• Discovered 4 novel AEs: asthenia, malaise, product dose omission, and anxiety.
• No high-priority clinical events; moderate priority events included acne, hypertension, facial swelling, and weight gain.

Conclusions:

• Nefecon exhibits a favorable real-world safety profile in IgA nephropathy patients.
• The study identified novel AEs and subgroup-specific risks, enhancing early clinical vigilance.
• Findings contribute valuable data for ongoing Nefecon safety monitoring.